[1]周庆菊,李蓉.MODY2的认识及诊疗进展[J].国际内分泌代谢杂志,2016,36(03):180-183.[doi:10.3760/cma.j.issn.1673-4157.2016.03.09]
 Zhou Qingju,Li Rong..The cognition, diagnosis and treatment of MODY2[J].International Journal of Endocrinology and Metabolism,2016,36(03):180-183.[doi:10.3760/cma.j.issn.1673-4157.2016.03.09]
点击复制

MODY2的认识及诊疗进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年03期
页码:
180-183
栏目:
综述
出版日期:
2016-05-20

文章信息/Info

Title:
The cognition, diagnosis and treatment of MODY2
作者:
周庆菊李蓉
400042 重庆医科大学附属第一医院内分泌内科
Author(s):
Zhou Qingju Li Rong.
Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China
关键词:
青少年发病的成年型糖尿病2型 糖尿病 葡萄糖激酶 基因突变
Keywords:
Maturity-onset diabetes of the young 2 Diabetes mellitus Glucokinase Gene mutation
DOI:
10.3760/cma.j.issn.1673-4157.2016.03.09
摘要:
青少年发病的成年型糖尿病2型(MODY2)由葡萄糖激酶(GCK)基因突变所致,以空腹血糖及糖化血红蛋白水平轻度升高并保持稳定状态为主要表现,多不增加糖尿病并发症及相关代谢疾病的发生风险,无需降糖治疗。但对于妊娠期患者,若胎儿未携带突变基因,妊娠相关并发症及巨大儿发生风险增加,故此类患者需积极降糖治疗。
Abstract:
Maturity-onset diabetes of the young(MODY)caused by glucokinase(GCK)gene mutation is called MODY2. Previous study has demonstrated that the levels of fasting blood glucose and glycated hemoglobin(HbA1c)in MODY2 increase slightly and keep stable. It will not raise the incidence of complications of diabetes and other related metabolic disease. Accordingly, there is no need to give treatment. But for pregnant women, if the fetus is without GCK gene mutation,the risk of macrosomia and perinatal morbidity will increase. Therefore, it is necessary to lower the level of blood glucose.

参考文献/References:

[1] Anιk A, Catlι G, Abac A, et al. Maturity-onset diabetes of the young(MODY): an update[J].J Pediatr Endocrinol Metab,2015,28(3-4):251-263. DOI: 10.1515/jpem-2014-0384.
[2] 刘丽梅.青少年的成人起病型糖尿病的特点、基因诊断与转化医学[J].中华糖尿病杂志,2014,6(1):5-9. DOI:10.3760/cma.j.issn.1674-5809.2014.01.002.
[3] 沈云峰,翁建平.葡萄糖激酶基因突变与功能学研究进展[J].国际内科学杂志,2008,35(12):692-695.
[4] Chakera AJ, Steele AM, Gloyn AL,et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation[J].Diabetes Care,2015,38(7):1383-1392. DOI: 10.2337/dc14-2769.
[5] Froguel P, Vaxillaire M, Sun F,et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus[J].Nature,1992,356(6365):162-164.
[6] Stride A, Vaxillaire M, Tuomi T,et al. The genetic abnormality in the beta cell determines the response to an oral glucose load[J].Diabetologia,2002,45(3):427-435.
[7] 李秀珍,刘丽,梁翠丽,等.青少年发病的成年型糖尿病2型一家系[J].中华儿科杂志,2014,52(11):867-871. DOI:10.3760/cma.j.issn.0578-1310.2014.11.017.
[8] 王志新,于淼,郑佳,等.四例中国青少年的成人起病型糖尿病2型家系的临床与分子遗传学研究[J].中华糖尿病杂志,2014,6(1):21-26. DOI:10.3760/cma.j.issn.1674-5809.2014.01.005.
[9] Bacon S, Schmid J, McCarthy A,et al. The clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes of the young[J].Am J Obstet Gynecol,2015,213(2):236.e1-e7. DOI: 10.1016/j.ajog.2015.04.037.
[10] 王晓春,徐克前,刘惠宁,等.胎儿宫内生长受限与胰岛素样生长因子-Ⅱ关系的研究[J].中国妇幼保健,2002,17(6):368,383. DOI: 10.3969/j.issn.1001-4411.2002.06.023.
[11] 朱明慧.血胰岛素及C肽与胎儿生长发育关系的研究[D].中山大学,2006.
[12] Colom C, Corcoy R. Maturity onset diabetes of the young and pregnancy[J].Best Pract Res Clin Endocrinol Metab,2010,24(4):605-615. DOI: 10.1016/j.beem.2010.05.008.
[13] Steele AM, Shields BM, Wensley KJ,et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia[J].JAMA,2014,311(3):279-286. DOI: 10.1001/jama.2013.283980.
[14] Pruhova S, Dusatkova P, Kraml PJ,et al. Chronic mild hyperglycemia in GCK-MODY patients does not increase carotid intima-media thickness[J].Int J Endocrinol,2013,2013:718254. DOI: 10.1155/2013/718254.
[15] Spégel P, Ekholm E, Tuomi T,et al. Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene(MODY2)[J].Diabetes,2013,62(2):653-661. DOI: 10.2337/db12-0827.
[16] Ellard S, Bellanné-Chantelot C, Hattersley AT,et al. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young[J]. Diabetologia,2008,51(4):546-553. DOI: 10.1007/s00125-008-0942-y.
[17] Gandica RG, Chung WK, Deng L,et al. Identifying monogenic diabetes in a pediatric cohort with presumed type 1 diabetes[J].Pediatr Diabetes,2015,16(3):227-233. DOI: 10.1111/pedi.12150.
[18] Stride A, Shields B, Gill-Carey O,et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia[J]. Diabetologia,2014,57(1):54-56. DOI: 10.1007/s00125-013-3075-x.
[19] Ellard S, Beards F, Allen LI,et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria[J].Diabetologia,2000,43(2):250-253.
[20] Chakera AJ, Spyer G, Vincent N,et al. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort[J].Diabetes Care,2014,37(5):1230-1236. DOI: 10.2337/dc13-2248.
[21] Hindmarsh PC, Geary MP, Rodeck CH,et al. Intrauterine growth and its relationship to size and shape at birth[J].Pediatr Res, 2002,52(2):263-268.
[22] Chakera AJ, Carleton VL, Ellard S,et al. Antenatal diagnosis of fetal genotype determines if maternal hyperglycemia due to a glucokinase mutation requires treatment[J].Diabetes Care,2012,35(9):1832-1834. DOI: 10.2337/dc12-0151.

相似文献/References:

[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
 Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(03):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
 Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
 Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(03):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制 ——2014年美国糖尿病协会“杰出科学成就奖” 演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
 Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(03):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
 Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(03):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
 Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(03):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
 Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(03):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
 Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(03):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
 Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(03):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
 Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]

备注/Memo

备注/Memo:
基金项目:国家临床重点专科建设项目(2011)
更新日期/Last Update: 2016-05-20